[
  {
    "title": "Remdesivir Market Analysis",
    "content": "Remdesivir has shown significant efficacy in treating COVID-19. Market potential estimated at $2.5B globally. Key competitors include Gilead's own portfolio.",
    "date": "2023-10-15"
  },
  {
    "title": "Pembrolizumab Competitive Intelligence",
    "content": "Merck's Keytruda dominates the PD-1 inhibitor market. Patent expires in 2030. Opportunities in combination therapies.",
    "date": "2023-09-20"
  },
  {
    "title": "Insulin Market Trends",
    "content": "Diabetes prevalence increasing. Biosimilars entering market. Focus on long-acting insulins for better patient compliance.",
    "date": "2023-11-05"
  },
  {
    "title": "Aspirin Patent Landscape",
    "content": "Generic aspirin widely available. New formulations for cardiovascular prevention showing promise.",
    "date": "2023-08-30"
  },
  {
    "title": "Morphine Regulatory Update",
    "content": "Morphine remains a key opioid for severe pain management. Regulatory scrutiny increasing due to addiction concerns. Market stable at $3.2B with controlled distribution.",
    "date": "2023-07-15"
  },
  {
    "title": "Bivalirudin Anticoagulation Study",
    "content": "Bivalirudin shows advantages over heparin in PCI procedures. Lower bleeding risk. Market growing at 6.8% annually. Patent protection until 2010.",
    "date": "2023-09-10"
  }
]